AGP Executive Report
Last update: 9 hours agoObesity Care: A new triple-action treatment produced 23% weight loss in people with type 2 diabetes. Lilly Israel is also launching personalized digital support for eligible patients prescribed diabetes or obesity medicines. Patient Safety: Philips recalled ultrasound systems after four reported deaths. Separately, detections of a rare, often-fatal brain fungus quadrupled at a US reference lab from 2023 to 2025, prompting calls for national surveillance. Cancer Screening: An FDA advisory panel voted 7-2 that GRAIL’s Galleri multi-cancer blood test’s benefits outweigh its risks for adults 50 and older; a final decision is expected in the coming months. Drug Supply: Experts cited overseas production dependence, manufacturer incentives and regulatory burdens as contributors to drug shortages. GSK plans to invest more than $800 million in Pennsylvania biologics production, creating over 300 jobs. Heart Failure: At-home subcutaneous furosemide reduced hospitalizations for worsening heart failure, potentially offering patients an alternative to hospital-based treatment.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[American Pharmacists Month: The Many Career Paths US Pharmacists Explore]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/29343176-949105358-5821c99f28c0e2a784ea0b86a92549d21e501195-1800x1200-200x133.jpeg)
